Skip to main content
Top
Published in: International Urology and Nephrology 4/2010

Open Access 01-12-2010 | Urology – Original Paper

New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT

Authors: Shoichi Iida, Hideki Ishida, Tadahiko Tokumoto, Kazuya Omoto, Hiroki Shirakawa, Tomokazu Shimizu, Hiroyuki Amano, Kiyoshi Setoguchi, Taiji Nozaki, Daisuke Toki, Daisuke Tokita, Kazunari Tanabe

Published in: International Urology and Nephrology | Issue 4/2010

Login to get access

Abstract

Background

To evaluate the role of the oral glucose tolerance test (OGTT) before transplantation and to examine the risk factors for new-onset diabetes after transplantation (NODAT) during long-term follow-up of renal transplant recipients receiving FK-based therapy.

Methods

The study evaluated 378 patients pre-transplantation using the OGTT and assigned them to one of three groups: Group 1, normal pattern; Group 2, impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) pattern (IFG/IGT); and Group 3, DM pattern.

Results

Although the incidence of NODAT was higher in Group 3 than in groups 1 and 2, no significant difference was found between the three groups with regard to graft survival during long-term follow-up. Multivariate analysis showed that only a family history of diabetes was a significant factor determining NODAT progression.

Conclusions

Impaired glucose tolerance appears to be a threshold influencing NODAT; however, it was not a significant factor in graft survival. Careful monitoring and management based on the result of the pre-transplantation OGTT appear to prevent the deterioration of impaired glucose tolerance in renal transplant recipients receiving FK-based therapy, even when a pre-operative OGTT shows impaired glycemic control.
Literature
1.
go back to reference Massy ZA, Kasiske BL (1996) Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 7:971–977PubMed Massy ZA, Kasiske BL (1996) Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 7:971–977PubMed
2.
go back to reference Aakhus S, Dahl K, Wideroe TE (1999) Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648–654CrossRefPubMed Aakhus S, Dahl K, Wideroe TE (1999) Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648–654CrossRefPubMed
3.
go back to reference Kasiske BL (2000) Cardiovascular disease after renal transplantation. Semin Nephrol 20:176–187PubMed Kasiske BL (2000) Cardiovascular disease after renal transplantation. Semin Nephrol 20:176–187PubMed
4.
go back to reference Jindal RM, Sidner RA, Milgrom ML (1997) Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16:242–257CrossRefPubMed Jindal RM, Sidner RA, Milgrom ML (1997) Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16:242–257CrossRefPubMed
5.
go back to reference Weir MR, Fink JC (1999) Risk for post transplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34:1–13CrossRefPubMed Weir MR, Fink JC (1999) Risk for post transplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34:1–13CrossRefPubMed
6.
go back to reference Krentz AJ, Dmitrewski J, Mayer D, Nattrass M (1995) Effects of immunosuppressive agents on glucose metabolism. Clin Immunother 4:103–123 Krentz AJ, Dmitrewski J, Mayer D, Nattrass M (1995) Effects of immunosuppressive agents on glucose metabolism. Clin Immunother 4:103–123
7.
go back to reference Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus and cyclosporine for immuno-suppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983CrossRefPubMed Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus and cyclosporine for immuno-suppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983CrossRefPubMed
8.
go back to reference Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus Multicenter Renal Study Group. Transplantation 64:436–443CrossRefPubMed Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus Multicenter Renal Study Group. Transplantation 64:436–443CrossRefPubMed
9.
go back to reference Knoll GA, Bell RC (1999) Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. Br Med J 318:1104–1107 Knoll GA, Bell RC (1999) Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. Br Med J 318:1104–1107
10.
go back to reference Van Duijnhoven EM, Boots JMM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP (2001) Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrology 12:583–588 Van Duijnhoven EM, Boots JMM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP (2001) Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrology 12:583–588
11.
go back to reference Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K et al (2001) β-cell dysfunction rather than insulin resistance is the main contributing factor for development of postrenal transplantation diabetes mellitus. Transplantation 71:1417–1423CrossRefPubMed Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K et al (2001) β-cell dysfunction rather than insulin resistance is the main contributing factor for development of postrenal transplantation diabetes mellitus. Transplantation 71:1417–1423CrossRefPubMed
12.
go back to reference Ekstrand A, Ahonen J, Gronhagen-Riska C, Groop L (1989) Mechanisms of insulin resistance after kidney transplantation. Transplantation 48:563–568PubMed Ekstrand A, Ahonen J, Gronhagen-Riska C, Groop L (1989) Mechanisms of insulin resistance after kidney transplantation. Transplantation 48:563–568PubMed
13.
go back to reference Fivush B, Green OC, Porter CC, Balfe JW, O’Regan S, Gahl WA (1987) Pancreatic endocrine insufficiency in post transplant cystinosis. Am J Dis Child 141:1087–1108PubMed Fivush B, Green OC, Porter CC, Balfe JW, O’Regan S, Gahl WA (1987) Pancreatic endocrine insufficiency in post transplant cystinosis. Am J Dis Child 141:1087–1108PubMed
14.
go back to reference Filler G, Amendt P, von Bredow MA, Rohde W, Ehrich JHH (1998) Slowly deteriorating insulin secretion and C-peptide production characterizes diabetes mellitus in infantile cystinosis. Eur J Pediatr 157:738–742CrossRefPubMed Filler G, Amendt P, von Bredow MA, Rohde W, Ehrich JHH (1998) Slowly deteriorating insulin secretion and C-peptide production characterizes diabetes mellitus in infantile cystinosis. Eur J Pediatr 157:738–742CrossRefPubMed
15.
go back to reference Schmitz O, Orskov L, Lund S, Moller N, Christiansen JS, Orskov H (1993) Glucose metabolism in chronic renal failure with reference to GH treatment of uremic children. J Pediatr Endocrinol 6:53–55PubMed Schmitz O, Orskov L, Lund S, Moller N, Christiansen JS, Orskov H (1993) Glucose metabolism in chronic renal failure with reference to GH treatment of uremic children. J Pediatr Endocrinol 6:53–55PubMed
16.
go back to reference Tanabe K, Tokumoto T, Ishida H et al (2004) Excellent outcome of ABO incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 36:2175–2177CrossRefPubMed Tanabe K, Tokumoto T, Ishida H et al (2004) Excellent outcome of ABO incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 36:2175–2177CrossRefPubMed
17.
go back to reference Ishida H, Miyamoto N, Shirakawa H et al (2007) Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation-single center analysis. Am J Transplant 7:825–831CrossRefPubMed Ishida H, Miyamoto N, Shirakawa H et al (2007) Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation-single center analysis. Am J Transplant 7:825–831CrossRefPubMed
18.
go back to reference Davidson J, Wilkinson A, Dantal J et al. (2003) New-onset diabetes after transplantation: 2003 International Consensus Guidelines. In: Proceedings of an international expert panel meeting. Barcelona, Spain, February 19, 2003. Transplantation 75(suppl): SS3 Davidson J, Wilkinson A, Dantal J et al. (2003) New-onset diabetes after transplantation: 2003 International Consensus Guidelines. In: Proceedings of an international expert panel meeting. Barcelona, Spain, February 19, 2003. Transplantation 75(suppl): SS3
19.
go back to reference Racusen LC, Solez K, Colvin RB et al (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713–723CrossRefPubMed Racusen LC, Solez K, Colvin RB et al (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713–723CrossRefPubMed
20.
go back to reference Scantlebury V, Shapiro R, Fung J et al (1991) New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23:3160–3170 Scantlebury V, Shapiro R, Fung J et al (1991) New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23:3160–3170
21.
go back to reference Mathew JT, Rao M, Job V et al (2003) Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 18:164–171CrossRefPubMed Mathew JT, Rao M, Job V et al (2003) Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 18:164–171CrossRefPubMed
22.
go back to reference Hjelmesaeth J, Hartmann A, Kofstad J et al (1997) Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64:979CrossRefPubMed Hjelmesaeth J, Hartmann A, Kofstad J et al (1997) Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64:979CrossRefPubMed
23.
go back to reference Todo S, Fung JJ, Starzl TE et al (1990) Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 212:295CrossRefPubMed Todo S, Fung JJ, Starzl TE et al (1990) Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 212:295CrossRefPubMed
24.
go back to reference Suga A, Kishi Y, Fujikawa Y et al (2003) Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. Transplant Proc 35:263–265CrossRefPubMed Suga A, Kishi Y, Fujikawa Y et al (2003) Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. Transplant Proc 35:263–265CrossRefPubMed
25.
go back to reference Sezer S, Bilgic A, Uyar M, Arat Z, Ozdemir FN, Haberal M (2006) Risk factors for development of posttransplant diabetes mellitus in renal recipients. Transplant Proc 38:529–532CrossRefPubMed Sezer S, Bilgic A, Uyar M, Arat Z, Ozdemir FN, Haberal M (2006) Risk factors for development of posttransplant diabetes mellitus in renal recipients. Transplant Proc 38:529–532CrossRefPubMed
26.
go back to reference Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y (2008) Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post transplantation diabetes mellitus (PTDM). Nephrol Dial Transpl 23:2033–2042CrossRef Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y (2008) Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post transplantation diabetes mellitus (PTDM). Nephrol Dial Transpl 23:2033–2042CrossRef
Metadata
Title
New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT
Authors
Shoichi Iida
Hideki Ishida
Tadahiko Tokumoto
Kazuya Omoto
Hiroki Shirakawa
Tomokazu Shimizu
Hiroyuki Amano
Kiyoshi Setoguchi
Taiji Nozaki
Daisuke Toki
Daisuke Tokita
Kazunari Tanabe
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9712-0

Other articles of this Issue 4/2010

International Urology and Nephrology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine